Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma
Abstract: Introduction: Ipilimumab and nivolumab are checkpoint inhibitors that are known to cause a multitude of inflammatory ocular adverse events. Here we report a patient with poliosis and symptomatic depigmentation of the choroid and retinal pigment epithelium (RPE) associated with checkpoint inhibitor therapy for cutaneous melanoma. Case Presentation: The patient presented with floaters in both eyes and concerns for intraocular metastases of metastatic cutaneous melanoma after 1 month of therapy with ipilimumab and nivolumab. External examination revealed poliosis of her eyebrows and eyelashes. Fundus photography demonstrated multiple 1–3 disc-diameter hypopigmented placoid flat areas in the RPE/choroid exposing underlying choroidal vessels in both eyes. At subsequent evaluation 7 months later (after an additional 6 months of checkpoint inhibitor therapy), the lesions appeared more blanched. Evaluation nearly 20 months after the initial presentation showed no significant changes from her prior visit despite cessation of checkpoint inhibitor therapy for 13 months. Conclusion: Checkpoint inhibitor therapy for cutaneous melanoma metastases can cause depigmentation of the choroid and RPE that must be differentiated from progression of intraocular melanoma.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma ; volume:17 ; number:1 ; year:2024 ; pages:122-127 ; extent:6
Case reports in oncology ; 17, Heft 1 (2024), 122-127 (gesamt 6)
- Creator
-
Cotton, Caroline C.
Chandrabhatla, Anirudha S.
Higgins, Mackenzie L.
Shildkrot, Yevgeniy
- DOI
-
10.1159/000535745
- URN
-
urn:nbn:de:101:1-2406270100156.842976948769
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cotton, Caroline C.
- Chandrabhatla, Anirudha S.
- Higgins, Mackenzie L.
- Shildkrot, Yevgeniy
Other Objects (12)
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma